8-K: Zynex Reports 10% Revenue Growth in Q1 2024, Despite Cyber Incident Impact

Zynex, Inc. announced a 10% year-over-year revenue increase to $46.5 million for the first quarter of 2024, although results were slightly below guidance due to a cyber incident affecting insurer payments.

Summary

• Zynex reported a 10% increase in revenue for the first quarter of 2024, reaching $46.5 million, compared to $42.2 million in the same period last year.
• The company's revenue was slightly below the guided $47.5 million due to payment delays from insurers caused by a cyber incident.
• Despite the revenue shortfall, Zynex reaffirmed its full-year 2024 revenue guidance of at least $227 million, expecting to recover the delayed revenue throughout the year.
• Net income for the quarter was $10,000, resulting in diluted earnings per share of $0.00, a decrease from $1.6 million and $0.04 per share in Q1 2023.
• Orders increased by 23% year-over-year, marking the eighth consecutive quarter of record order numbers.
• Cash flow from operations increased by 7% year-over-year to $2.1 million.
• Zynex repurchased $13.4 million of its common stock during the quarter, and $78.5 million over the last 24 months.
• The company received FDA clearance for its next-generation M-Wave NMES device and introduced two new therapy products: the Zynex Pro Hybrid LSO and the Zynex DynaComp Cold Compression.
• Zynex has four pre-revenue hospital monitoring products in the pipeline, with the FDA 510(k) submission for NiCO tracking to the second half of 2024.
• The company expects a 23% increase in net revenue for 2024 compared to 2023, and diluted EPS of at least $0.50 per share, an 85% increase compared to 2023.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While revenue growth and order increases are positive, the significant drop in net income and EPS, along with the impact of the cyber incident, temper the overall sentiment. The reaffirmation of full-year guidance and new product launches provide some optimism.

Positives

• Zynex achieved a 10% year-over-year revenue increase in Q1 2024.
• The company experienced a 23% year-over-year increase in orders, marking a record for the eighth consecutive quarter.
• Cash flow from operations increased by 7% year-over-year.
• Zynex successfully repurchased $13.4 million of its common stock in Q1 2024.
• The company received FDA clearance for its next-generation M-Wave NMES device.
• Zynex introduced two new therapy products, expanding its product offerings.
• The company reaffirmed its full-year 2024 revenue guidance of at least $227 million.
• Zynex expects a 23% increase in net revenue for 2024 compared to 2023.
• The company anticipates a significant increase in diluted EPS for 2024, estimated to be at least $0.50 per share, an 85% increase compared to 2023.

Negatives

• Q1 2024 revenue underperformed guidance by $1 million due to payment delays caused by a cyber incident affecting insurers.
• Net income for Q1 2024 was only $10,000, a significant decrease from $1.6 million in Q1 2023.
• Diluted EPS for Q1 2024 was $0.00, down from $0.04 in Q1 2023.

Risks

• The company experienced payment delays from insurers due to a cyber incident, impacting Q1 2024 revenue.
• The company's net income and diluted EPS decreased significantly compared to the same quarter last year.
• The company is dependent on reimbursement for its products from health insurance companies.
• The company is dependent on third party manufacturers to produce its products on time and to specifications.
• The company faces risks related to the acceptance of new products by doctors and hospitals.
• The company faces competition from larger competitors with greater financial resources.
• The company needs to keep pace with technological changes.
• The company's future performance is subject to market conditions and economic factors, such as interest rate fluctuations.

Future Outlook

Zynex expects 2024 net revenue to increase approximately 23% compared to 2023, with a full-year revenue target of at least $227 million. Diluted EPS is expected to be at least $0.50 per share for 2024, an 85% increase compared to 2023. Second quarter 2024 revenue is estimated to be at least $52.0 million, an increase of approximately 16% from Q2 2023. Second quarter Diluted EPS is estimated to be at least $0.08.

Management Comments

• Thomas Sandgaard, President and CEO of Zynex, stated that the company continued its focus on order growth, FDA approvals of next-generation devices, and new therapy products during the first quarter of 2024.
• Sandgaard noted that approximately $1.0 million in revenue was impacted by payment delays due to a cyber incident affecting insurers, but expects to recognize that revenue over the remainder of the year.
• Sandgaard highlighted the 23% improvement in orders year-over-year for the pain management division.
• Sandgaard mentioned the company's continued share repurchase plan, with $13.4 million repurchased in Q1 2024 and $78.5 million over the last twenty-four months.
• Sandgaard stated that the company is diversifying its pain management revenue stream with the introduction of two new therapy products.
• Sandgaard mentioned that the FDA 510(k) submission for NiCO is now tracking to the second half of 2024.
• Sandgaard concluded that innovative new products and aggressive promotion from an expanding direct salesforce are diversifying revenue streams and ensuring sustained growth.

Industry Context

Zynex operates in the medical technology industry, specifically focusing on non-invasive medical devices for pain management, rehabilitation, and patient monitoring. The company's results are impacted by factors such as FDA approvals, reimbursement from health insurance companies, and competition from other medical device manufacturers. The cyber incident affecting insurer payments highlights a broader industry risk related to data security and its impact on financial operations.

Comparison to Industry Standards

• Zynex's 10% revenue growth in Q1 2024 is a solid performance in the medical device industry, although the cyber incident and its impact on revenue is a concern.
• The 23% increase in orders is a strong indicator of market demand for Zynex's products, and is a positive sign compared to competitors.
• The company's gross profit margin of 80% is healthy and indicates efficient cost management.
• The decrease in net income and EPS is a concern, and is below industry standards for companies of this size.
• The company's stock repurchase program is a positive sign for investors, and is a common practice in the industry.
• The introduction of new products and the expansion of the sales force are positive steps for future growth, and are in line with industry best practices.
• The company's focus on innovation and new product development is a key differentiator in the competitive medical device market.
• The company's reliance on third-party manufacturers is a common practice in the industry, but also presents a risk.

Stakeholder Impact

• Shareholders may be concerned about the decrease in net income and EPS, but may be encouraged by the revenue growth, order increases, and stock repurchase program.
• Employees may be impacted by the company's performance and future growth plans.
• Customers will benefit from the introduction of new products and therapies.
• Suppliers may be impacted by the company's production and sales volumes.
• Creditors will be interested in the company's financial health and ability to meet its obligations.

Next Steps

• The company will focus on recognizing the delayed revenue over the remainder of the year.
• Zynex will continue to develop and launch new products, including the four pre-revenue hospital monitoring products.
• The company will continue its share repurchase program.
• Zynex will work towards the FDA 510(k) submission for NiCO in the second half of 2024.
• The company will continue to expand its direct salesforce.

Key Dates

Keywords

medical devices, pain management, rehabilitation, non-invasive, FDA, NMES, revenue, EBITDA, stock repurchase, cyber incident, orders, EPS